- V****art G (2008). "Non-peptide arginine-vasopressin antagonists: the
vaptans". Lancet. 371 (9624): 1624–32. doi:10.1016/S0140-6736(08)60695-9. PMID 18468546...
-
medications (amphotericin B, orlistat, ifosfamide, ofloxacin, cidofovir,
vaptans). In
addition to
kidney and
systemic disorders,
nephrogenic diabetes insipidus...
- recommended.
There is
tentative evidence that
vasopressin receptor antagonists (
vaptans), such as conivaptan, may be
slightly more
effective than
fluid restriction...
- bendroflumethiazide, chlorothiazide, hydrochlorothiazide), triamterene,
vaptans Gene doping, the use of
nucleic acids that may
alter genome sequences and/or...
-
surface expression of P-selectin
through exocytosis of Weibel-Palade
bodies from
endothelial cells AVP,
desmopressin "-
vaptan" diuretics, i.e. tolvaptan...
-
vasopressin (AVP) and
treatment with
arginine vasopressin receptor antagonists (
vaptans) in
congestive heart failure,
liver cirrhosis and
syndrome of inappropriate...
- V****art G (May 2008). "Non-peptide arginine-vasopressin antagonists: the
vaptans". Lancet. 371 (9624): 1624–32. doi:10.1016/S0140-6736(08)60695-9. PMID 18468546...
-
water retention.
Vasopressin receptor antagonists include the new
class of "
vaptan drugs" such as conivaptan, tolvaptan, mozavaptan, lixivaptan, satavaptan...
-
effect of aquaresis, or
electrolyte free
water excretion. This
property of
vaptans explains their use as
therapies to
treat euvolemic and
hypervolemic hyponatremia...
